УПРАВЛЕНИЕ НЕЖЕЛАТЕЛЬНЫМИ ЯВЛЕНИЯМИ, ВОЗНИКАЮЩИМИ НА ФОНЕ ПРИЕМА ПЕРАМПАНЕЛА

1. French J.A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012; 79: 589-96.

2. French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2013; 54: 117-25.

3. Krauss G.L. et al. Randomized phase III study 306: adjunctive perampanel for partial onset seizures. Neurology. 2012; 78: 1408-15.

4. Krauss G.L. et al. Perampanel, a selective, noncompetitive a-amino-3- hydroxy-5-methyl-4-isooxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onsetseizures: Interim results from phase III, extension study 307. Epilepsia. 2013; 54: 126-34.

5. Rektor I. et al. Perampanel Study 207: long term open label evaluation in patients with epilepsy. Acta Neurol Scand 2012; 126: 263-9.

6. Steinhoff B.J. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-9.

7. Franco V. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013; 70: 35-40.

8. Davies S., Heyman I., Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003; 45: 292-5.

9. Инструкция по медицинскому применению прапарата Файкомпа РУ ЛП 002200 от 23.08.2013.